Business
Biodesix Announces Publication Further Validating the Use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients With Cancer
Additionally, data associated with the GeneStrat® ddPCR™ and Genestrat NGS™ blood tests will be presented at the American Association for Cancer Research
About this update from Biodesix, Inc.
[{"type":"text","content":"\nAdditionally, data associated with the GeneStrat® ddPCR™ and Genestrat NGS™ blood tests will be presented at the American Association for Cancer Research (AACR)\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.” This peer-reviewed publication further validates the GeneStrat NGS test and the use of multiple classes of tumor markers in circulating free nucleic acid analysis as a surrogate for tumor tissue biopsies. i\n\n“These data extend on Biodesix’ testing of plasma for somatic nucleotide variants and indels in circulating nucleic acids by detecting amplifications, fusions and exon skipping. We can broadly assay for the major variant classes which includes actionable mutations in support of comprehensive molecular testing in lung cancer,” said Gary Pestano, Ph.D., Chief Development Officer, Biodesix.\n\nAdditionally, Biodesix will present data associated with the GeneStrat ddPCR and NGS blood tests in a poster presentation focused on reporting validation studies of key actionable mutations in NSCLC entitled: Analytic and clinical validation of a new pan-cancer NGS liquid biopsy test for the detection of copy number variations, fusions/exon skipping, somatic variants and indels (Abstract number 5323), at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. The full abstract can be found on the official AACR website here. Poster presentations will be viewable after April 8th, 2022.\n\nThe company believes that the coupling of highly sensitive, rapid stand-alone droplet digital™ PCR (ddPCR) and the NGS techniques offers more comprehensive blood-based testing support for patients with non-small cell lung cancer (NSCLC) and provides clinically relevant information both before and after targeted treatment of patients with cancer.\n\nAbout Biodesix\n\nBiodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by comb...